Role of Steroids in Malignant Bowel Obstruction
DOI:
https://doi.org/10.17140/PMHCOJ-2-116Keywords:
Malignant Bowel Obstruction (MBO), Steroids, CancerAbstract
Various cancers such as ovarian, stomach, colon or pancreas may present with mechanical bowel obstruction. This may be partial or total depending on the pathology and extent of the disease. On presentation, the patient requires appropriate assessment and management as per underlying pathology and assessment findings. Comprehensive medical and surgical management strategies are required to manage malignant bowel obstruction effectively. Steroids have been reported for their beneficial use in malignant bowel obstruction. We review the usefulness of steroids in patients presenting with malignant bowel obstruction.
References
Tuca A, Guell E, Losada EM, Codorniu N. Malignant bowel obstruction in advanced cancer patients: Epidemiology, manage-ment, and factors influencing spontaneous resolution. Cancer Manag Res. 2012; 4: 159-169. doi: 10.2147/CMAR.S29297
Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for management of bowel obstruction in pa-tients with end-stage cancer. Support Care Cancer. 2001; 9: 223- 233.
Fainsinger R, Spachynski K, Hanson J, et al. Symptom con-trolin terminally ill patients with malignant bowel obstruc-tion (MBO). J Pain Symptom Manage. 1994; 9(1): 12-18. doi: 10.1016/0885-3924(94)90141-4
Reenan J. Surgery for bowel obstruction in ovarian cancer. AMA J Ethics. 2004; 6: 1-3. Web site. http://journalofethics.ama-assn.org/2004/10/cprl1-0410.html. Accessed June 19, 2016.
Levy MH, Back A, Baker JN, et al. NCCN (National Compre-hensive Cancer Network) clinical practice guidelines in oncol-ogy: Palliative care (version 2.2013). J Nati Compr Canc Netw. 2013; 1: 18-19.
Ripamonti CI, Easson AM, Gerdes H. Management of ma-lignant bowel obstruction. Eur J Cancer. 2008; 44: 1105-1115.
Potluri V, Zhukovsky DS. Recent advances in malignant bow-el obstruction: An interface of old and new. Curr Pain Headache Rep. 2003; 7: 270-278. doi: 10.1007/s11916-003-0047-8
Tradounsky G. Palliation of gastrointestinal obstruction. Can Fam Physician. 2012; 58: 648-652. Web site. https://www.ncbi. nlm.nih.gov/pmc/articles/PMC3374686/. Accessed June 19, 2016.
Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG. Bioavailability of oral dexamethasone. Clinical Phar-macy and Therapeutics. 1975; 18(2): 205-209. doi: 10.1002/ cpt1975182205
MercadanteS, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction. J Pain Symp-tom Manage. 2007; 33(3): 217-223. doi: 10.1016/j.jpainsym-man.2006.06.014
Hardy J, Ling J, Mansi J, et al. Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of ma-lignant bowel obstruction. Palliat Med. 1998; 12: 437-442. doi: 10.1191/026921698666334766
Philip J, Do T, Lickiss N, et al. Corticosteroids in gastroin-testinal obstruction in patients with gynaecological cancer. Int J Gynecol Cancer. 1997; 7: 87.
Philip J, Lickiss N, Grant PT, Hacker NF. Corticosteroids in the management of bowel obstruction on a gynecological unit. Gynecol Oncol. 1999; 74: 68-73. doi: 10.1006/gyno.1999.5406
Laval G, Girarder J, Lassauniere J, et al. The use of steroids in the management of inoperable intestinal obstruction in ter-minal cancer patients: Do they remove the obstruction? Palliat Med. 2000; 14(1): 3-10. doi: 10.1191/026921600669298725
Laval G, Benazech BM, Guirimand F, et al. Recommenda-tions for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage. 2014; 48: 75-91. doi: 10.1016/j.jpain-symman.2013.08.022
Feuer D, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruc-tion in advanced gynaecological and gastrointestinal cancers. Ann Oncol. 1999; 10: 1035-1041. doi: 10.1023/A:1008361102808
Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000; CD001219. doi: 10.1002/14651858.CD001219
Mercadante S, Avola G, Maddaloni S, Salamone G, Aragona F, Rodolico V. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients. Support Care Cancer. 1996; 4: 393-394. doi: 10.1007/BF01788848
Mercadante S, Ferrera P, Villari P, et al. Aggressive pharma-cological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage. 2004; 28(4): 412-416. doi: 10.1016/j. jpainsymman.2004.01.007
Laval G, Arvieux C, Stefani L, et al. Protocol for the treat-ment of malignant inoperable bowel obstruction: A prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manage. 2006; 31: 502-512. doi: 10.1016/j.jpainsym-man.2005.10.009
Murakami H, Matsumoto H, Nakamura M, Hirai T, Ya-maguchi Y. Octreotide acetate steroid combination therapy for malignant gastrointestinal obstruction. Anri Cancer Research. 2013; 33: 5557-5560. Web site. http://ar.iiarjournals.org/con-tent/33/12/5557.long. Accessed June 19, 2016.
Ahmad F, Jeffries C, Longford E, et al. Guidelines for the medical management of malignant bowel obstruction. Cheshire and Merseyside palliative and end of life care strategic clini-cal network group guidelines. NHS. 2015. Web site. www. cmscnsenate.nhs.uk. Accessed July 1, 2016.
Bhatia R, Reid C. BPCC (Bristol Palliative Care Collabora-tive) steroid guidelines. Palliative care guidelines for the use of steroids in patients with cancer. P T. 2016; 18: 205-209. Web site. www.stpetershospice.org.uk. Accessed June 19, 2016.
Shih A, Jackson KC. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother. 2007; 21: 69-76. doi: 10.1080/J354v21n04_14
The Bone and Tooth Society, National Osteoporosis So-ciety. Glucocorticoid-induced osteoporosis: A concise guide for prevention and treatment. London, UK: Royal College of Physicians; 2002. Web site. http://www.dbh.nhs.uk/Library/ Pharmacy_Medicines_Management/Formulary/Formulary_S6/ Glucocortoid-induced%20Osteoporosis.pdf. Accessed June 10, 2016.
CSM/MCA (Committee on safety of medicines and medi-cines control agency). Withdrawal of systemic corticosteroids. Current Problems in Pharmacovigilance. 1998; 24: 5A.
Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: Role of non-steroidal anti-inflam-matory drugs. Ann Intern Med. 1991; 114: 735-740. Web site. http://annals.org/aim/article/1077526/corticosteroid-use-peptic -ulcer-disease-role-nonsteroidal-anti-inflammatory-drugs. Ac-cessed June 19, 2016.
Twycross R. Corticosteroids in advanced cancer. BMJ. 1992; 305: 969-970. Web site. https://www.ncbi.nlm.nih.gov/pmc/ar-ticles/PMC1884052/. Accessed June 19, 2016.
Landrum LM, Blank S, Chen L, et al. Comprehensive care in gynecologic oncology: The importance of palliative care. Gynecologic Oncology. 2015; 137: 193-202. doi: 10.1016/j. ygyno.2015.02.026
Fletcher A, Murray A. Guidelines for use of steroids in cancer patients: Wigan and Leigh Hospice. Web site. www.re-searchgate.net. Accessed June 10, 2016.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Palliative Medicine and Hospice Care (PMHC) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
